Ling‐Ming Tseng

13.9k total citations · 2 hit papers
228 papers, 8.8k citations indexed

About

Ling‐Ming Tseng is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Ling‐Ming Tseng has authored 228 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Oncology, 86 papers in Molecular Biology and 75 papers in Cancer Research. Recurrent topics in Ling‐Ming Tseng's work include HER2/EGFR in Cancer Research (50 papers), Breast Cancer Treatment Studies (33 papers) and Advanced Breast Cancer Therapies (25 papers). Ling‐Ming Tseng is often cited by papers focused on HER2/EGFR in Cancer Research (50 papers), Breast Cancer Treatment Studies (33 papers) and Advanced Breast Cancer Therapies (25 papers). Ling‐Ming Tseng collaborates with scholars based in Taiwan, United States and South Korea. Ling‐Ming Tseng's co-authors include Hsin‐Chen Lee, Tadeusz Pieńkowski, Pinuccia Valagussa, Young‐Hyuck Im, Luca Gianni, Giulia Bianchi, Seock‐Ah Im, Juan de la Haba-Rodríguez, Semiglazov Vf and Aňa Lluch and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Ling‐Ming Tseng

219 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

2011 1.5k citations Ling‐Ming Tseng et al. profile →
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

2016 555 citations Ling‐Ming Tseng et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ling‐Ming Tseng Taiwan	43	4.9k	3.6k	3.0k	1.6k	1.3k	228	8.8k
Thomas Fleming Germany	34	6.5k 1.3×	3.1k 0.9×	2.1k 0.7×	1.7k 1.1×	3.0k 2.2×	110	11.9k
Linda T. Vahdat United States	52	7.5k 1.5×	3.6k 1.0×	2.7k 0.9×	2.1k 1.3×	837 0.6×	236	11.5k
Francesco Cognetti Italy	46	5.0k 1.0×	2.4k 0.7×	1.7k 0.6×	2.3k 1.5×	1.0k 0.8×	221	8.5k
Marcus Schmidt Germany	42	5.0k 1.0×	2.4k 0.7×	2.7k 0.9×	2.8k 1.8×	785 0.6×	297	9.0k
Sabine C. Linn Netherlands	48	4.7k 1.0×	3.2k 0.9×	3.4k 1.1×	2.4k 1.5×	910 0.7×	231	9.1k
Daniele Generali Italy	42	3.1k 0.6×	2.5k 0.7×	2.1k 0.7×	1.7k 1.1×	490 0.4×	232	6.2k
Ingrid A. Mayer United States	46	6.0k 1.2×	5.0k 1.4×	3.4k 1.1×	3.3k 2.1×	1.8k 1.4×	210	12.0k
Rodrigo Dienstmann Spain	37	3.4k 0.7×	3.2k 0.9×	2.2k 0.7×	1.7k 1.1×	486 0.4×	179	7.0k
Elizabeth Claire Dees United States	34	4.5k 0.9×	3.0k 0.8×	2.9k 1.0×	1.4k 0.9×	395 0.3×	127	7.9k
Andrew D. Seidman United States	50	8.1k 1.7×	2.2k 0.6×	2.2k 0.7×	2.5k 1.6×	2.0k 1.5×	211	11.1k

Countries citing papers authored by Ling‐Ming Tseng

Since Specialization

Citations

This map shows the geographic impact of Ling‐Ming Tseng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling‐Ming Tseng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling‐Ming Tseng more than expected).

Fields of papers citing papers by Ling‐Ming Tseng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling‐Ming Tseng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling‐Ming Tseng. The network helps show where Ling‐Ming Tseng may publish in the future.

Co-authorship network of co-authors of Ling‐Ming Tseng

This figure shows the co-authorship network connecting the top 25 collaborators of Ling‐Ming Tseng. A scholar is included among the top collaborators of Ling‐Ming Tseng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ling‐Ming Tseng. Ling‐Ming Tseng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ku, Wei‐Chi, et al.. (2025). Integrating functional proteomics and next generation sequencing reveals potential therapeutic targets for Taiwanese breast cancer. Clinical Proteomics. 22(1). 4–4. 1 indexed citations

Wang, Sheng‐Fan, Yin‐Kai Chao, Chern‐En Chiang, et al.. (2025). Impact of PIK3CA Mutations on the Clinical Benefits of CDK 4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: An Updated Pairwise and Network Meta-Analysis. Journal of Cancer. 16(10). 3065–3079.

Huang, Sheng‐Miauh, Ling‐Ming Tseng, Chi‐Cheng Huang, et al.. (2025). The development and validation testing of a comprehensive frailty assessment in women with breast cancer. BMC Women s Health. 25(1). 46–46. 1 indexed citations

Tsai, Yi-Fang, et al.. (2025). Multimodal analgesia with thoracic paravertebral block decrease pain and side effects in mastectomy patients. Journal of the Chinese Medical Association. 88(6). 486–491. 1 indexed citations

Hu, Yu‐Wen, Cheng-Ying Shiau, Pin‐I Huang, et al.. (2023). Association of radiation dose to cardiac substructures with major ischaemic events following breast cancer radiotherapy. European Heart Journal. 44(45). 4796–4807. 19 indexed citations

Tsai, Yi‐Fang, et al.. (2023). Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases. Breast Cancer Research and Treatment. 201(3). 547–560. 2 indexed citations

Lin, Po‐Han, Ling‐Ming Tseng, Yi‐Hsuan Lee, et al.. (2022). Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders. Journal of the Formosan Medical Association. 121(12). 2538–2547. 11 indexed citations

Huang, Ching-Shui, et al.. (2021). Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study. Journal of Personalized Medicine. 11(7). 613–613. 2 indexed citations

Chen, Mei‐Chun, Sheng‐Fan Wang, Jeng‐Fan Lo, et al.. (2021). Salubrinal Enhances Cancer Cell Death during Glucose Deprivation through the Upregulation of xCT and Mitochondrial Oxidative Stress. Biomedicines. 9(9). 1101–1101. 8 indexed citations

10.

Wang, Yen‐Yun, Steven Lo, Ling‐Ming Tseng, et al.. (2019). Visfatin Mediates Malignant Behaviors through Adipose-Derived Stem Cells Intermediary in Breast Cancer. Cancers. 12(1). 29–29. 31 indexed citations

11.

Wu, Ching-Fang, et al.. (2019). Developing a Decision-Aid Website for Breast Cancer Surgery: An Action Research Approach. Journal of Medical Internet Research. 21(2). e10404–e10404. 10 indexed citations

12.

Sheu, Shuh‐Jen, et al.. (2019). Developing a Web-Based Comic for Newly Diagnosed Women With Breast Cancer: An Action Research Approach. Journal of Medical Internet Research. 21(2). e10716–e10716. 15 indexed citations

13.

Lu, Yen‐Shen, Tom Wei‐Wu Chen, Ching‐Hung Lin, et al.. (2015). Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. Clinical Cancer Research. 21(8). 1851–1858. 71 indexed citations

14.

Hung, Man‐Hsin, Chun‐Yu Liu, Cheng‐Ying Shiau, et al.. (2014). Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients. PLoS ONE. 9(2). e89389–e89389. 54 indexed citations

15.

Horak, Christine E., Lajos Pusztai, Guan Xing, et al.. (2013). Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research. 19(6). 1587–1595. 83 indexed citations

16.

Chen, Dar‐Ren, et al.. (2013). Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid.. PubMed. 33(12). 5543–7. 1 indexed citations

17.

Huang, Sheng‐Miauh, Chen‐Jei Tai, Kuan‐Chia Lin, et al.. (2012). A Comparative Study of Symptoms and Quality of Life Among Patients With Breast Cancer Receiving Target, Chemotherapy, or Combined Therapy. Cancer Nursing. 36(4). 317–325. 17 indexed citations

18.

Chen, Yi‐Wei, Kuan-Hsuan Chen, Pin‐I Huang, et al.. (2010). Cucurbitacin I Suppressed Stem-Like Property and Enhanced Radiation-Induced Apoptosis in Head and Neck Squamous Carcinoma–Derived CD44+ALDH1+ Cells. Molecular Cancer Therapeutics. 9(11). 2879–2892. 110 indexed citations

19.

Lü, Jing, Ming Tan, Wen-Chien Huang, et al.. (2009). Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance. Clinical Cancer Research. 15(4). 1326–1334. 65 indexed citations

20.

Chang, Chun–Ju, Jen‐Hwey Chiu, Ling‐Ming Tseng, et al.. (2006). Si-Wu-Tang and its constituents promote mammary duct cell proliferation by up-regulation of HER-2 signaling. Menopause The Journal of The North American Menopause Society. 13(6). 967–976. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact